Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nbt0505-529 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of the 's intervention mechanism and clinical application in ischemic stroke.
Front Pharmacol
January 2025
College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: (BC), also named Niuhuang in Chinese, is utilized as a resuscitation drug in Traditional Chinese Medicine (TCM) for the treatment of neurological disorders. Ischemic stroke (IS) is a significant global public health issue that currently lacks safe and effective therapeutic drugs. Ongoing efforts are focused on identifying effective treatment strategies from Traditional, Complementary, and Integrative Medicine.
View Article and Find Full Text PDF[Trigeminal neuralgia - Overview].
Laeknabladid
February 2025
Department of Neurology, University Hospital of Iceland, Reykjavik, Iceland.
Trigeminal neuralgia is the most common cause of facial pain in individuals over 50 years old and can have a profoundly negative impact on quality of life. Epidemiological studies have measured the annual incidence of trigeminal neuralgia at around 4-5 cases per 100,000 inhabitants per year. In Iceland, this would amount to about 16-20 new cases annually.
View Article and Find Full Text PDFDNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system.
Front Pharmacol
January 2025
Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Introduction: DNA methylation inhibitors have been approved for the prevention of Acute Myeloid Leukemia (AML), and their safety profile is not fully characterized. This study was aimed at evaluating the adverse drug reactions (ADRs) of DNA methylation inhibitors by analyzing the individual case safety reports (ICSRs) collected in the EudraVigilance (EV) database.
Materials And Methods: The EV database managed by the European Medicines Agency was adopted.
Emerging treatments for sarcoma: from 2024 onward.
Expert Opin Emerg Drugs
January 2025
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Introduction: Sarcomas are a rare and diverse group of mesenchymal-origin solid tumors, constituting only 1% of adult malignancies and classified into soft tissue and bone sarcomas. For localized disease, surgery and radiotherapy remain the cornerstone treatments. However, systemic options for advanced stages are limited, with an overall survival of approximately 20 months.
View Article and Find Full Text PDF: emerging challenges in pathogenesis and drug resistance.
Future Microbiol
January 2025
Infectious Diseases Department, The First Hospital of China Medical University, Shenyang, Liaoning, China.
() is an opportunistic pathogenic fungus that often causes severe infections in immunosuppressed patients. Among species, is the most pathogenic and lethal species. Current research faces challenges related to unknown pathogenic mechanisms, complex resistance mechanisms, insufficiently rapid and accurate diagnostic methods, and insufficient research on susceptibility to infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!